AbbVie AI Strategy: Mapping AI Across the Value Chain
How AbbVie uses AI on its own work: AI mapped across its value chain, a regulatory writing tool, AI partners in R&D and early wins meant to fund the rest. Updated November 2026.
Prescription medicines in immunology, oncology, neuroscience and eye care, plus aesthetics
AbbVie names an enterprise AI approach, AI@AbbVie, but has no AI strategy document. This profile is inferred from 2025 and 2026 releases and interviews.
Read the company sourceWhere AbbVie Is Going with AI
AbbVie is mapping AI across every function of its value chain, from drug discovery to manufacturing. It calls its enterprise approach AI@AbbVie and says AI is being embedded across research and development, operations and other core functions (AbbVie, September 2026). AbbVie has published no AI strategy document, so this profile is inferred from company releases and executive interviews.
The plan is for early wins to pay for the rest. Sarah Nam, Vice President of AI Strategy and Partnerships at the time, said in an October 2025 conversation with Anthropic that early successes “can then self-fund the rest of the AI initiatives.” She added: “We’re taking a very value chain-based approach.”
The focus has four parts.
- Drug discovery: AI to optimize the efficacy, safety and behavior of drug candidates, with partners such as Iambic
- Clinical development: AI for trial design and patient selection, with partners such as Valkai to cut manual work
- Regulatory writing: Gaia, an AbbVie tool built on large language models that drafts regulatory documents
- Manufacturing: AI that predicts equipment maintenance and guides automation, plus a pilot digital twin of a manufacturing room (AbbVie)
What It Takes: A Dedicated AI Lead, Partners and People Readiness
AbbVie gives AI strategy a dedicated leader. Nam’s role combined setting AI priorities across the business with running AI partnerships and deals. In manufacturing, James Hughes is Vice President of Operations, AI and Digital Transformation.
AbbVie treats adoption as a people challenge. Nam said: “It’s not only a technology challenge, but it’s also really moving people’s hearts and minds.” AbbVie offers AI training at every level and names champions in each function, two pillars of AI change management.
Quality teams built their own AI accelerator. AbbVie’s operations quality group narrowed about 100 ideas to 10 priorities and built a community of more than 120 people across 11 functions (Pharmaceutical Online, July 2026). Paula Gamboa, Associate Director of Data Strategy and Innovation, said: “We realized AI wasn’t really the hard thing; everything around it was.”
Plant teams are learning data skills. A Data Academy at AbbVie’s North Chicago manufacturing site offers 90 short courses across seven tracks.
Governance is stated but not detailed. AbbVie says its AI use is guided by human expertise and ethical use, and its quality accelerator covers intake, prioritization, governance, data quality and adoption. AbbVie has published no AI governance framework.
AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):
- Fluency floor: Not published. AbbVie offers AI training at every level, but it has set no required level for all staff.
- Highest level evidenced: Level 3 (Integrating), company-claimed. Gaia drafts regulatory documents inside the regulatory writing workflow, saving about 40% to 60% of the time on some documents, according to Nam. The figure has not been independently verified.
- Portfolio design: AbbVie maps AI use cases function by function across its value chain and adds outside AI partners in discovery and clinical development.
How AbbVie Measures Results
AbbVie reports few AI results for its own work. The figures it has shared are company-claimed:
- Regulatory writing: about 40% to 60% time savings on some documents drafted with Gaia
- Quality operations: about 100 AI ideas narrowed to 10 priorities, with 58 volunteers offering to help
Gaps remain. AbbVie gives no company-wide value figure, even though its approach relies on early wins to fund later work. Putting a number on those wins is the step from AI adoption to AI value.
Next markers: results from the Valkai and Iambic partnerships, a value figure for AI@AbbVie, wider training and headcount for 2026.
Change log
- October 2025: Nam describes AbbVie’s value chain approach to AI.
- July 2026: AbbVie’s operations quality team describes its AI accelerator.
- September 2026: AbbVie announces AI partnerships with Iambic for drug discovery and Valkai for clinical development.
The Bottom Line
- Disclosure: 4 of 4. AbbVie answers each question at least in part, with one measured result.
- AI is mapped to the value chain, function by function.
- Early wins are meant to fund later AI work.
- Level 3 is evidenced in regulatory writing, on company-claimed results.
- The say-do gap is measurement. A self-funding model needs a value figure, and AbbVie has not published one.
- Watch the partnerships. The test is whether Valkai and Iambic shorten development timelines.
Revenue, Headcount and Revenue per Employee
What the numbers show: Revenue rose 5% from 2022 to 2025 while headcount rose 14%, so revenue per employee fell 8%, to about $1.07 million. Revenue dipped in 2023 as Humira lost US exclusivity, and headcount grew in 2024 with the ImmunoGen and Cerevel acquisitions. These figures do not show that AI caused any change.
Revenue, headcount and revenue per employee, FY2022 to FY2025
- FY2022: $58.05bn revenue, 50,000 employees, $1.16M per employee
- FY2023: $54.32bn revenue, 50,000 employees, $1.09M per employee
- FY2024: $56.33bn revenue, 55,000 employees, $1.02M per employee
- FY2025: $61.16bn revenue, 57,000 employees, $1.07M per employee
Change, FY2022 to FY2025: revenue up 5%, headcount up 14%, revenue per employee down 8%.
Notes: Revenue is net revenues, as reported. Headcount is approximate, at year-end. AbbVie acquired ImmunoGen and Cerevel Therapeutics in 2024, which added employees.
These figures give context on scale and productivity. They do not show that AI caused any change. Sources: AbbVie 10-K filings.
How AbbVie Compares with US Pharma Peers
We looked at how AbbVie compares with other US pharmaceutical companies in the index. Here is how they stack up.
| Company | Disclosure | AI owner | Fluency floor | Governance | AI value reported | Revenue per employee |
|---|---|---|---|---|---|---|
| AbbVie | 4 of 4 | VP of AI Strategy and Partnerships | Not published; training offered at all levels | Human expertise and ethical use; no published framework | One result (regulatory writing), no total | $1.07M |
| Amgen | 3 of 4 | EVP of research, AI and data; SVP and CTO | Not published; ChatGPT Enterprise across the company | Published AI Vision; phased rollouts | None published | $1.17M |
| Bristol Myers Squibb | 4 of 4 | EVP and Chief Digital and Technology Officer | Not published; frontier models for all staff | Enterprise governance and audit controls; humans decide | Targets set, no results | $1.48M |
| Eli Lilly | 3 of 4 | Chief AI Officer | Level 1, by expectation | Eight principles, board briefings | No: capacity and deals | $1.30M |
| Gilead Sciences | 2 of 4 | Global CIO; no AI leader named | Not published; AI coach in pilot | Six published AI principles | None published | $1.73M |
| Johnson & Johnson | 4 of 4 | EVP and CIO; each function governs its own AI | Level 1, training required before access (2024) | Function-led governance; central AI board removed | Results by use case, no total | $682k |
| Merck | 4 of 4 | CEO sponsors five AI programs; CIO leads technology | Not published; 80%+ use the AI platform | Human review of AI drafts; no published framework | Results by use case, no total | $867k |
| Pfizer | 3 of 4 | Chief AI, Data and Analytics Officer | Level 1, 98% trained | Three principles, a board risk topic | Inside wider cost programs | $834k |
| Moderna AI Pacesetter | 2 of 4 | Chief People and Digital Technology Officer | Level 1, by expectation | Mentioned, not described | No: adoption figures | $414k |
Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. Rows marked AI Pacesetter or Notable are companies outside the S&P 100 and STOXX Europe 50. They are shown for contrast and are not counted in any index figure. See all companies in the AI Strategy Index.
Frequently Asked Questions
What is AbbVie’s AI strategy for its own work?
AbbVie maps AI across its value chain under an approach it calls AI@AbbVie. It is embedding AI in research and development, operations and other core functions.
Who leads AI at AbbVie?
Chairman and CEO Robert A. Michael sets the company’s direction, and a dedicated AI strategy team sets priorities and partnerships. Sarah Nam led that work as Vice President of AI Strategy and Partnerships in 2025.
Which AI tools does AbbVie use?
AbbVie built Gaia, a tool based on large language models, for regulatory writing. It also uses Claude from Anthropic, and it works with AI partners such as Iambic and Valkai.
Is AbbVie cutting jobs because of AI?
The sources reviewed show no AI-linked job cuts at AbbVie. Headcount rose to about 57,000 at the end of 2025.
How is this profile put together?
Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.
About the AI Strategy Index
The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.
See all company profiles